| abstract |
THIS INVENTION IS REFERRED TO CERTAIN SUBSTITUTED 6,6HETEROBYCLICAL DERIVATIVES, TO PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND TO ADMINISTRATION PROCEDURES THEREOF TO SUBJECTS WHO NEED THEIR ANTAGONIST ACTIVITY OF THE CORTIC LIBERATION FACTOR. THE SUBSTITUTED HETERO-CYCLE DERIVATIVES CLAIMED IN THIS CASE PRESENT ANTAGONIST ACTIVITY OF THE CORTICOTROPIN RELEASE FACTOR (CRF) (HORMONE) (CRH). THESE COMPOUNDS HAVE THE CHEMICAL STRUCTURE (I), IN WHICH A, B, D, E, G, K, R3 AND R5 ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. |